venetoclax + dinaciclib

**venetoclax + dinaciclib** is an experimental combination therapy of two small molecule inhibitors investigated primarily for the treatment of hematologic malignancies. Venetoclax is a potent, selective inhibitor of BCL-2, an anti-apoptotic protein overexpressed in various leukemias, which promotes cancer cell survival through inhibition of apoptosis. Dinaciclib is a selective cyclin-dependent kinase (CDK) inhibitor, primarily targeting CDK1, CDK2, CDK5, and especially CDK9, resulting in downregulation of MCL-1 protein—a key mechanism of resistance to BCL-2 inhibition. The combination targets two critical survival factors in leukemia cells, leading to synergistic induction of apoptosis, especially in hypodiploid B-lineage acute lymphoblastic leukemia (ALL) and in relapsed or refractory acute myeloid leukemia (AML). Preclinical studies have demonstrated robust synergistic cytotoxicity and reduced leukemic burden with acceptable tolerability, and an open-label Phase 1 clinical trial is ongoing in R/R AML patients[1][3][5][7].

Other names

venetoclax + dinaciclib